semaglutide shortage 2025 Novo Nordisk's officially concludes in the US, spelling major threat for weight loss drug compounders As of February 21, 2025,
Description
All participants had HbA1c levels between 7.0% and 9.5% plus a body mass index of at least 23 kg/m2 atbaseline
PlexusDx offers compounded semaglutide injections and evidence-based strategies that deliver measurable results without breaking your budget
FDA approval is anticipated in 2026, through the FDA's national priority voucher program, positioning Lilly to compete aggressively in the oral segment
Most assessments are reviewed the same day
Features hydrolysed Type I & III collagen for easy mixing
